LMR Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

LMR Partners’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-27,505	Closed	-$447K	–	567
2014 Q1	$447K	Buy	+27,505	New	+$391K	0.06%	144

Other funds holding VNDA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

SCA

Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LMR Partners's VNDA Position: Q2 2014 in Review

LMR Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2014, closing a stake of 27,505 shares — an estimated $447K sold.

LMR Partners first reported a position in VNDA in Q1 2014 and held it in 1 quarter. The position peaked at $447K in Q1 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q2 2014.

LMR Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
LMR Partners sold 27,505 Vanda Pharmaceuticals shares in Q2 2014, an estimated $447K.
LMR Partners first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 1 quarter.
LMR Partners's Vanda Pharmaceuticals position peaked at $447K in Q1 2014.
110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2014.

Based on LMR Partners's 13F filing for Q2 2014, filed 10 Jul 2014.